Case Study 2 Sample Clauses

Case Study 2. In Case study 2, there was a moderate-large amount of missing data that ranged from 5% to 45% for individual variables. The study had 1,094 patients who met the inclusion and exclusion criteria; however, only 585 (53.5% of the original sample) patients had complete data for analysis. Multiple linear regression was performed to evaluated the association between GLP-1 agonists and reduction in HbA1c levels controlling for age, gender, race, baseline HbA1c, BMI, CCI, history of myocardial infarction, congestive heart failure, hypertension, obesity, and dyslipidemia. Complete-case analysis and multiple imputation method were performed and the results were compared to the crude analysis. In all three methods, there were no significant association between exenatide and reduction in HbA1c relative to liraglutide. Multiple imputation method provided the same conclusion as the complete-case analysis and crude analysis.
AutoNDA by SimpleDocs
Case Study 2. In Case study 2, patients who were prescribed exenatide had no significant association with change in HbA1c compared to liraglutide while controlling for potential confounders. In contrast, Xxxx, et al.78 reported that liraglutide once daily had a significantly greater reduction in HbA1c compared with exenatide twice daily in a 26-week, open-labeled, parallel group, multinational study [-1.12% (SE, 0.08) versus -0.79% (0.08), P<0.0001]. The small sample size of the liraglutide cohort may reflect confounding by indication which is a form of selection bias.79 It is plausible that patients who were prescribed liraglutide may have some other indication than diabetes that is different from exenatide patients. The VHA national formulary does not include GLP-1 agonists. However, during the study period of interest, exenatide twice daily had a criteria for use document that formulary managers in the VHA used to determine whether or not the patient is eligible to receive the liraglutide based on specific criteria; liraglutide did not (xxxx://xxx.xxx.xx.xxx). Therefore, it is speculated, that providers and pharmacists preferred to use exenatide as a consequence of formulary guidelines being available. This may indicate that patients on lirgalutide could have been approved based on a specific clinical indication (other than diabetes) that would prevent them from using exenatide (e.g., previous history of exenatide, contraindication, or patient/provider preferences). Future studies will need to randomize exenatide and liraglutide to diabetic patients based on baseline HbA1c in order to reduce bias and potential confounding. Regardless, multiple imputation provided similar conclusions as the complete-case analysis and crude analysis. The confidence limit from the multiple imputation method was narrower compared to the complete-case analysis and crude analysis; however, this improvement in precision did not change the conclusion that there was no significant association between exenatide and change in HbA1c compared to liraglutide. In addition, multiple imputation provided benefit by increasing the sample size of the small cohort of liraglutide patients.
Case Study 2. The First Harvest
Case Study 2. Oxycodone 10mg modified release tablet (8386J) Maximum Price to Concessional Patients $6.60 $6.60 Maximum Price to General Patients $39.92 $41.00
Case Study 2. Xxxxxx, a 27 year old male, works in a mine outside of town, and comes home for a long weekend each month. He is single, and reports meeting up with women on his long weekends. He has 2 women he regularly reconnects with at a local bar when he is back in town. He presents to the health facility today because he has had a persistent cough that will not go away. His mother worriers he has pneumonia, and asked him to see a doctor before returning to the mine. Otherwise, he feels fine. Xxxxxx’s TB and HIV tests are positive. Sibongile, a 22 year old female, works as a hair dresser. She is married with a three year old child at home. Her husband is her only reported sex partner, since they married four years ago. She received an HIV testing during ANC with her first child, and was HIV-negative. She presents to the clinic today with nausea and fatigue, and would like a pregnancy test. Otherwise, she feels fine. Sibongile’s pregnancy and HIV tests are positive. Xxxxx, a 36 year old female, is a single mother. Her children are 14, 11 and 7 years old. She lost her job two years ago after her husband died. She finds small jobs here and there, and has been selling sex when money is too little to pay the bills. She has two male partners she sees regularly, one from church, and one from her neighborhood. She came today for an HIV test after hearing an advertisement on the radio about the importance of knowing your HIV status. She feels fine, but would like to know her HIV status for peace of mind. Xxxxx’ HIV test is positive. Xxxxxx, a 4-year old boy, presents to the outpatient department (OPD) at a health center today with his mother. He has had a cold for the past week. The intake counsellor asks his mother 4 questions:

Related to Case Study 2

  • The Study 1The parties must comply with, and conduct the Study in accordance with, the Protocol and any conditions of the Reviewing HREC. In addition the parties must comply with the following, as applicable:

  • Feasibility Study A feasibility study will identify the potential costs, service quality and other benefits which would result from contracting out the work in question. The cost analysis for the feasibility study shall not include the Employer’s indirect overhead costs for existing salaries or wages and benefits for administrative staff or for rent, equipment, utilities, and materials, except to the extent that such costs are attributable solely to performing the services to be contracted out. Upon completion of the feasibility study, the Employer agrees to furnish the Union with a copy if the feasibility study, the bid from the Apparent Successful Bidder and all pertinent information upon which the Employer based its decision to contract out the work including, but not limited to, the total cost savings the Employer anticipates. The Employer shall not go forward with contracting out the work in question if more than sixty percent (60%) of any projected savings resulting from the contracting out are attributable to lower employee wage and benefit costs.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Study Population ‌ Infants who underwent creation of an enterostomy receiving postoperative care and awaiting enterostomy closure: to be assessed for eligibility: n = 201 to be assigned to the study: n = 106 to be analysed: n = 106 Duration of intervention per patient of the intervention group: 6 weeks between enterostomy creation and enterostomy closure Follow-up per patient: 3 months, 6 months and 12 months post enterostomy closure, following enterostomy closure (12-month follow-up only applicable for patients that are recruited early enough to complete this follow-up within the 48 month of overall study duration).

  • Phase 2 Phase 2 is expected to consist of Member Nodes and a select number of Nodes operated by non-Members. The non-Member Nodes will be required to comply with Node hosting terms as set forth by the Council, which may be amended from time to time (the “General Node Terms”).

  • Protocol The attached Protocol shall be an integral part of this Agreement.

  • Development Phase contractual phase initiated with the approval of ANP for the Development Plan and which is extended during the Production Phase while investments in xxxxx, equipment, and facilities for the Production of Oil and Gas according to the Best Practices of the Oil Industry are required.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Synchronization, Commissioning and Commercial Operation 4.1.1 The Power Producer shall give at least fifteen (15) days written notice to the SLDC / ALDC / DISCOM as the case may be, of the date on which it intends to synchronize the Power Project to the Grid System. 4.1.2 Subject to Article 4.1.1, the Power Project may be synchronized by the Power Producer to the Grid System when it meets all the connection conditions prescribed in the Grid Code and otherwise meets all other Indian legal requirements for synchronization to the Grid System. 4.1.3 The synchronization equipment and all necessary arrangements / equipment including Remote Terminal Unit (RTU) for scheduling of power generated from the Project and transmission of data to the concerned authority as per applicable regulation shall be installed by the Power Producer at its generation facility of the Power Project at its own cost. The Power Producer shall synchronize its system with the Grid System only after the approval of GETCO / SLDC / ALDC and GEDA. 4.1.4 The Power Producer shall immediately after each synchronization / tripping of generator, inform the sub-station of the Grid System to which the Power Project is electrically connected in accordance with applicable Grid Code. 4.1.5 The Power Producer shall commission the Project within SCOD. 4.1.6 The Power Producer shall be required to obtain Developer and/ or Transfer Permission, Key Plan drawing etc, if required, from GEDA. In cases of conversion of land from Agricultural to Non-Agriculture, the commissioning shall be taken up by GEDA only upon submission of N.A. permission by the Power Producer. 4.1.7 The Power Producer shall be required to follow the Forecasting and Scheduling procedures as per the Regulations issued by Hon’ble GERC from time to time. It is to clarify that in terms of GERC (Forecasting, Scheduling, Deviation Settlement and Related Matters of Solar and Wind Generation Sources) Regulations, 2019 the procedures for Forecasting, Scheduling & Deviation Settlment are applicable to all solar generators having combined installed capacity above 1 MW connected to the State Grid / Substation including those connected via pooling stations.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!